1. At a Glance – The Biopharma Makeover Nobody Expected
Biocon Ltd is currently trading at ₹379, with a market cap of ₹61,505 crore, a P/E of 74.9, and a ROE of just 4.76%. Sounds expensive? Wait.
Q3 FY26 consolidated revenue came in at ₹4,173 crore, up 9% YoY, while core EBITDA surged to ₹1,221 crore with a 29% margin. Reported PAT stood at ₹144 crore for the quarter.
But here’s the spicy part:
- ₹4,150 crore raised via QIP in Jan 2026
- Structured debt fully retired
- Net debt now hovering around $1.1–1.2 billion
- Debt/EBITDA below 2.5x
- S&P upgraded rating to BB+
- Fitch outlook turned Positive
Three-month return? -7.5%.
Market confused? Probably.
Company transforming? Definitely.
The stock looks like a biotech thriller where the first half was messy, and now the climax is loading.
So the real question is:
Is this expensive mediocrity… or underappreciated restructuring genius?
Let’s dissect.
2. Introduction – From Biosimilar Chaos to “Biocon One”
Biocon has had more plot twists than a Netflix crime series.
First, it bought the Viatris biosimilars business.
Then it piled on structured debt.
Then ratings agencies started giving it the side-eye.
Then margins got squeezed.
And now?
Management says, “Relax, we’re merging everything into one clean, unified platform.”
The proposed integration of Biocon Biologics into Biocon aims to create a single listed entity combining biosimilars and generics. Unified governance. Consolidated cash flows. Cleaner capital allocation.
Translation?
No more confusing subsidiary structures. One balance sheet to rule them all.
Meanwhile:
- Biosimilars = 58% of FY25 revenue
- Research services = 23%
- Generics = 19%
They operate across India, Malaysia, and the US.
They sell in 120+ countries.
They are among the top 5 global biosimilar players.
But here’s the catch.
The market doesn’t reward ambition. It rewards execution.
And Biocon’s history of low ROE (5% over 3 years) tells us execution hasn’t always been magical.
So is FY26 the inflection year?
Or just another hopeful slide in an investor presentation?
Keep reading.
3. Business Model – WTF Do They
